Table 2.
Lymphocyte count and outcome of the included studies
| Author | Smoking (%) | COPD (%) | Poor outcome (%) | Lymphocyte count in good outcome (/μL) | Lymphocyte count in poor outcome (/μL) | Lymphopenia cutoff | Lymphopenia in good outcome (%) | Lymphopenia in poor outcome (%) |
|---|---|---|---|---|---|---|---|---|
| Ruan et al. 2020 [7] | NR | 2.0 | 68/150 (45%), death | 1420 (2140) | 600 (320) | NR | NR | NR |
| Yang et al. 2020 [6] | 4 | 7.6 (CLD) | 20/52 (38%), death | 740 (840) | 620 (370) | NR | NR | NR |
| Zhou et al. 2020 [20] | 5.7 | 3.1 | 54/191 (28%), death | 1100 (800–1500) | 600 (500–800) | NR | NR | NR |
| Chen et al. 2020 [23] | 13.8 | 4.9 | 31/123 (25%), death | 910 (410) | 700 (360) | NR | NR | NR |
| Huang et al. 2020 [5] | 7.3 | 2.4 | 13/41 (31%), ICU | 1000 (700–1100) | 400 (200–800) | ≤ 1000 | 15/28 (54%) | 11/13 (85%) |
| Wang et al. 2020 [24] | NR | 2.9 | 36/138 (26%), ICU | 900 (600–1200) | 800 (500–900) | NR | NR | NR |
| Cao et al. 2020 [25] | 5.6 | NR | 19/198 (9%), ICU | 1230 (860–1565) | 760 (530–940) | ≤ 1000 | 1/179 (0.6%) | 16/19 (84%) |
| Wu et al. 2020 [26] | NR | 2.5 (CLD) | 84/201 (41%), ARDS | 1080 (720–1450) | 670 (490–990) | NR | NR | NR |
| Liu et al. 2020 [27] | NR | 3.7 | 53/109 (48%), ARDS | 1000 (800–1400) | 700 (400–1100) | NR | NR | NR |
| Guan et al. 2020 [28] | 14.4 | 1.1 | 173/1099 (15%), severe | 1000 (800–1400) | 800 (600–1000) | ≤ 1500 | 584/726 (83.2%) | 147/153 (96.1%) |
| Liu et al. 2020 [29] | 6.4 | 10.0 | 11/78 (14%), severe | 1000 (680–1390) | 530 (300–1150) | NR | NR | NR |
| Zhang et al. 2020 [10] | NR | 2.7 | 55/221 (24%), severe | 900 (600–1200) | 700 (400–900) | ≤ 1100 | 115/166 (69%) | 48/55 (87%) |
| Zhang et al. 2020 [11] | 6.4 | 1.4 | 58/140 (34%), severe | 800 (600–1200) | 700 (500–1000) | ≤ 1100 | 58/82 (70.%) | 46/56 (82.1%) |
| Wan et al. 2020 [12] | 6.7 | 0.7 (CLD) | 40/135 (29%), severe | 1200 (800–1600) | 800 (600–1000) | ≤ 1100 | 36/95 (38%) | 32/40 (80%) |
| Qu et al. 2020 [13] | NR | NR | 3/30 (10%), severe | 1010 (450) | 1160 (550) | NR | NR | NR |
| Qin et al. 2020 [14] | 1.5 | 2.6 | 286/452 (63%), severe | 1000 (700–1300) | 800 (600–1100) | NR | NR | NR |
| Wang et al. 2020 [15] | 23.6 | 5.4 | 38/110 (34%), severe | 1210 (530) | 600 (310) | NR | NR | NR |
| Feng et al. 2020 [16] | 4.9 | 2.8 | 15/141 (10%), severe | 1200 (800–1600) | 700 (600–1000) | NR | NR | NR |
| Lei et al. 2020 [17] | NR | NR | 7/51 (13%), severe | 1300 (900–1700) | 370 (300–600) | NR | NR | NR |
| Liu et al. 2020 [18] | NR | NR | 13/40 (32.5%), severe | 1100 (800–1400) | 600 (600–800) | NR | NR | NR |
| Cai et al. 2020 [19] | NR | NR | 58/298 (19%), severe | 1300 (1000–1800) | 970 (650–1190) | ≤ 1100 | 75/240 (31.3%) | 39/58 (67%) |
| Liu et al. 2020 [21] | 6.6 | 8.2 | 17/61 (27%), severe | 1100 (900–1400) | 900 (700–1100) | NR | NR | NR |
| Tabata et al. 2020 [22] | 17.3 | 6.7 (CLD) | 28/104 (26%), severe | NR | NR | < 1200 | 19/76 (25%) | 16/28 (57.1%) |
Lymphocyte count presented as median (IQR) or mean (SD). Smoking includes current and/or former smoker
NR not reported, CLD chronic lung disease/pulmonary disease